Phase 2 N=70 Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers
Non-small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 9.95; 6.83 Months — p=0.0618
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=951 Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.
Overactive Bladder
Primary: Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12. — -1.01; -1.35; -1.40 UUI Episodes — p=0.002
Phase 2 N=21 The Effect of HFA - Beclomethasone Dipropionate Qvar on Bronchial Hyperreactivity in Preschool Children
Asthma · Bronchial Hyperresponsiveness
Primary: Adenosine Challenge Test — 18.46; 142.61 mg/ml
Phase 2 N=18 Interferon-beta1a (AVONEX) Treatment of Ulcerative Colitis
Ulcerative Colitis
Primary: Percent of Participants With at Least a 3 Point Drop in the Short Clinical Colitis Score (SCCAI) — 63 Percent of participants
Phase 2 N=107 Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246
Orthopoxviral Disease
Primary: Number of Study Participants Who Tolerated a Single Daily Oral ST-246 Dose as Determined by Safety Parameter Changes According to the DAIDS (Division of Acquired…
Phase 2 N=1,783 Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age
Varicella · Rubella · Mumps
Primary: Number of Subjects With Seroresponse for Antibodies to Varicella Virus (VZV) — 355; 440; 301 subjects
Phase 2 N=57 Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus
Infections, Bacterial
Primary: Plasma Retapumulin Pharmacokinetic Parameters by Treatment at Days 1 and 3 Evaluated by Plasma AUC After Dosing — 0.8663; 0.3816; 4.2802; 2.0881 ng.h /mL
Phase 2 N=107 V501 Immunogenicity Study in Females Age 9 to 17 Years (V501-028)
HPV Infections
Primary: Human Papilloma Virus (HPV) 6 Serum Antibody Titer at One Month After Completed Vaccination Series — 674.5; 7.0 Geometric Mean Titers (mMU/mL) — p=<0.001
Phase 2 N=45 A Study of CK-1827452 Infusion in Stable Heart Failure
Heart Failure
Primary: Change From Baseline of Systolic Ejection Time at Various CK-1827452 Plasma Concentrations — 84; 62; 42; 24 msec — p=0.8842
Phase 2 N=70 Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis
Amyloidosis
Primary: Maximum Tolerated Dose — 2 participants with DLT
Phase 2 N=45 Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer
Breast Cancer
Primary: Pathologic Complete Response (pCR) in the Breast — 4; 38; 3 participants
Phase 2 N=400 Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali
Plasmodium Falciparum Malaria
Primary: Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the First Vaccination — 0; 5; 0; 12 Participants
Phase 2 N=53 Pemetrexed Plus Cisplatin as First-Line Treatment in Stage IV or Recurrence of Gastric Cancer
Gastric Cancer
Primary: Percentage of Participants With Objective Response (Objective Response Rate) — 32.1; 67.9 percentage of responders
Phase 2 N=201 Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting
Coronary Artery Disease
Primary: Inhibition of Platelet Aggregation (IPA) to 20 Micromolar (μM) Adenosine Diphosphate (ADP) at 6 Hours After the Loading Dose — 74.81; 31.77 percent inhibition — p=<0.0001
Phase 2 N=152 Treatment Outcomes for Temporomandibular Disorders (TMD) Via the Clayton Intra-aural Device (CID) Clinical Trial
Temporomandibular Disorders
Primary: Change From Baseline In Craniomandibular Index (CMI) Scores At 3 Months (In A Scale) — .23; .20 Units on a scale — p=<0.0096